[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620994":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":40,"collaborators":25,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":25,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":25,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":25,"overallStatus":62,"whyStopped":25,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Daewon Pharmaceutical Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","cross-over",[13,14],"Drug: DW4421-T1","Drug: DW4421S-T1",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Cross-over",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","DW4421-T1","DW4421-T1 or DW4421S-T1",[9,16],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"DW4421S-T1",[9,16],[30],{"facility":31,"status":25,"city":32,"state":25,"zip":25,"country":33,"countryCode":25,"cosmosGeoPoint":34,"geoPoint":39,"contacts":25},"Chungbuk National University Hospital","Cheongju-si","South Korea",{"type":35,"coordinates":36},"Point",[37,38],127.48972,36.63722,{"lat":38,"lon":37},{"type":41,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100620994","phase-1-a-phase-1-clinical-trial-to-evaluate-the-safety-and-pharmacokinetics-of-dw4421-t1-and-dw4421s-t1-in-healthy-adult-volunteers-100620994",false,"NCT07364851","A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers","A Randomized, Open-label, Single-dose, 2-sequence, Two-period, Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult aged 19 to 50 (inclusive) years\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive)\n\nExclusion Criteria:\n\n* clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history",true,"ALL","19 Years","50 Years",{"count":54,"type":55},38,"ESTIMATED","INTERVENTIONAL",[58],"PHASE1","Safety and pharmacokinetic characteristics evaluation of DW4421-T1 and DW4421S-T1",[61],"Healthy Adult Volunteer","NOT_YET_RECRUITING","2026-01-18",{"date":65,"type":66},"2026-01-23","ACTUAL",{"date":68,"type":55},"2026-03-06",{"date":70,"type":55},"2026-08-30",{"name":5,"class":6},1]